Clinical characteristics and outcomes in diabetes patients admitted with COVID-19 in Dubai: a cross-sectional single centre study

Introduction

The burden of the Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2), which is known as COVID-19 has being increasing worldwide. According to World Health Organisation (WHO), COVID-19 was declared as an epidemic on 11th March 2020.¹ To date 49,069 cases have been reported in the United Arab Emirates (UAE) with 316 deaths.²

Recent studies have suggested that diabetes is a major risk factor contributing to severity of illness and mortality from COVID-19.³ For example, a meta-analysis of seven trials in China showed that 9.7% of 1576 patients with COVID-19 had diabetes.⁴ Diabetes is also a major risk factor for the development of a more severe pneumonia and clinical course due to COVID-19 infection, and occurs in around 20-30% of such patients. ⁵ In addition, poor glycaemic control whether related to diabetes or stress hyperglycemia is also known to be associated with poor patient outcomes including hospitalisation and death. ⁶ In a large population-based study in England, 23,804 COVID-19 related deaths were reported. Of these, one third occurred in people with diabetes: 7,466 (31·4%) with Type 2 and 365 (1·5%) with Type 1 diabetes.⁷

The aim of this Dubai-based, single-centre cross-sectional study was to assess the clinical characteristics and outcomes of patients with diabetes admitted with moderate to severe COVID-19 illness.

Methods

Results

A total of 103 patients admitted to hospital with confirmed COVID-19 had diabetes. During the same timeframe, 410 patients overall were admitted with COVID-19 infection. This gives a total proportion of persons admitted with COVID-19 infection and coexistent diabetes/prediabetes of 25%. 67% (n=69) of the COVID-19 diabetes cohort were male. Patients admitted with COVID-19 and diabetes represented 17 different ethnicities. Of these, 59.2% (n=61) were Asians and 35% (n=36) were from Arab countries. Mean age (SD) was 54 (±12.5) years. 73.8% (n=76) had other comorbidities including hypertension, ischaemic heart disease, dyslipidaemia, and chronic kidney disease (shown in Table 1). 9.7% patients were on ACE-I and 31.1% patients were on ARB on admission, which were continued as per individual clinical circumstances during admission with no obvious adverse effects.

Out of 103 patients, 3 patients (2.9%) had type 1 diabetes and 90 patients (87.4%) had type 2 diabetes. 6/90 patients were newly diagnosed with type 2 diabetes during admission. 10 patients (9.4%) had prediabetes, of which 9 had a new diagnosis on admission. Of those patients with known diabetes diagnosis, 8 patients were on basal insulin regimen and 6 patients on basal bolus insulin regimen (Table 2).

On admission investigations (Table 3), average random blood glucose in laboratory was 10.2 mmol/L. 56/103 (54%) patients had lymphopenia on admission. 65 patients had confirmed pneumonia radiologically. 38 patients had normal chest x-ray, 14 out of these had confirmed pneumonia on chest HRCT. 4 out of 103 patients were negative on laboratory RT-PCR but had radiologically confirmed COVID-19 pathognomonic changes.

Emergent treatments used to manage diabetes patients with COVID-19 and related outcomes are outlined in Table 4. Half of patients (48.5%) received glucocorticoids during admission.

61.2% patients needed insulin during admission and required an average of 29.6 units of insulin per 24 hours. 5 patients had documented hypoglycaemia (defined as blood glucose level < 4 mmol/L) on capillary blood glucose during admission (2 of them were on hydroxychloroquine; 4 on insulin; and one had end stage renal disease).

5 patients died. All of them were in ICU. 4 of them were of Asian origin, 2 males and 3 females. 3 of them were known to have type 2 diabetes and 2 had new diagnosis of prediabetes on admission. 2 of them were obese, one had end stage renal disease with known breast cancer. All of them had pneumonia and 4 of them developed acute respiratory distress syndrome with septic shock. Their average length of stay in hospital was 18 days.

The Survival curve (Figure 1) showed that out of the 5 deaths occurring among the 103 patients, 4 of these were among the group treated by both treatments’ hydroxychloroquine and glucocorticoids (as might be anticipated based on severity of illness). The median time of death was 21 [3 – 39] days.

• Download figure
• Open in new tab

Figure 1.

Survival curve using Kaplan Meier Method

Discussion

In this single-centre study in Dubai, 25% of patients (n=103) admitted with COVID-19 also had diabetes/prediabetes. 14.6% of this study cohort had new diagnosis diabetes/prediabetes on admission. According to International Diabetes Federation (IDF), prevalence of diabetes in UAE is 17.3% ⁸ and our data reflects this high background prevalence.

Most diabetes patients admitted to hospital with COVID-19 disease were males (67% [n=69]). This agrees with emerging studies showing that men with COVID-19 are at higher risk for developing severe outcomes including death than women. ^3,4,9 Patients admitted with COVID-19 and diabetes represented 17 different ethnicities (Dubai is a very multi-national society with more than 200 nationalities). Of these, 59.2% (n=61) were Asians and 35% (n=36) were from Arab countries. This finding is also consistent with other studies that suggest that people of Black, Asian, and Minority Ethnic (BAME) populations have increased risk and are predisposed to worser clinical courses and outcomes with COVID-19 infection than Caucasian counterparts.¹⁰ In addition, many individuals of BAME origin are also more likely to have diabetes/prediabetes. Also, in keeping with recent studies most patients in our cohort with diabetes/prediabetes and COVID-19 infection had other important comorbidities (n=76; 73.8%). This finding is consistent with diabetes and cardiovascular disease being key components of the metabolic syndrome. ¹¹ The metabolic syndrome is also associated with pro-inflammatory and pro-thrombotic states which may have important implications for persons affected with COVID-19, where these complications are especially common and troublesome. ¹²

Our laboratory data has shown that fibrinogen, D-dimer, ferritin and CRP levels on admission were higher in those subsequently requiring intensive care treatment. This is reflective of inflammatory cytokine response with COVID-19. Acute hyperglycaemia has shown upregulation of ACE2 gene which facilitates entry of virus inside the cells. With hyperglycaemia over long periods of time it downregulates ACE2 expression making the cells vulnerable to the inflammatory effects of virus.¹³ These laboratory tests can be used on admission to decide the severity of illness and level of care required by the patient (i.e. risk stratification).

Limitations of our study include the small sample size and retrospective nature of analysis. Therefore, more studies with large sample size would help in this guidance. Another limitation of our study is there is no control group of patients without diabetes to compare with (other than knowing absolute numbers of total patients admitted with COVID-19 during the same timeframe). In addition, because of the emergent nature of many new sick patients presenting with COVID-19 to our healthcare facility over a short timeframe, accurate characterisation of overweight/obese status was unavailable for the majority of our patients (and thus are not reported as comorbidities).

Conclusions

In this single-centre study in Dubai, 25% of patients admitted with COVID-19 also had diabetes/prediabetes. Most diabetes patients admitted to hospital with COVID-19 disease were males of Asian origin. 14.6% had new diagnosis of diabetes/prediabetes on admission. The majority of patients with diabetes/prediabetes and COVID-19 infection had other important comorbidities (n=76; 73.8%). Only 4 patients had negative COVID-19 RT-PCR but had pathognomonic changes of COVID-19 radiologically. Our comprehensive laboratory analysis revealed distinct abnormal patterns of biomarkers that are associated with poor prognosis: Fibrinogen, D-dimer, Ferritin and CRP levels were all statistically significantly higher (p<0.05) at presentation in patients who subsequently needed ICU care compared with those patients who remained ward-based. 28.2% overall needed ICU admission, out of which 5 patients died. More studies with larger sample sizes are needed to compare data of COVID-19 patients admitted with and without diabetes within the UAE region.

Funding source

None.

Conflicts of Interest

None